Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Ibogaine, derived from the iboga tree, shows therapeutic potential for various neurological and psychiatric conditions.
• Understanding its mechanism of action involves examining its effects on monoamine neurotransmitter transporters.

Purpose of the Study:

• To systematically investigate the effects of ibogaine, noribogaine, and iboga analogs on monoamine transporters.
• To elucidate the neurochemical mechanisms underlying ibogaine's therapeutic effects.

Main Methods:

• Cell-based fluorometry assays to assess VMAT2 transport function.
• Two-photon microscopy to visualize transporter activity in mouse brain.
• Uptake and release assays using radiolabeled serotonin in isolated brain synaptic vesicles.
• Inhibition assays for plasma membrane monoamine transporters (MATs), including SERT and OCT2.

Main Results:

• Ibogaine and noribogaine inhibit VMAT2 with submicromolar potency.
• Noribogaine was found to induce partial serotonin release from synaptic vesicles.
• Iboga compounds inhibit SERT and OCT2, with some analogs showing dual VMAT2 and SERT inhibition.
• These dual inhibitors were termed "Synaptic Reuptake Inhibitors" (SynRIs).

Conclusions:

• The SynRI profile provides a model for ibogaine's neurochemical effects and therapeutic potential.
• This updated understanding of iboga pharmacology, termed "matrix pharmacology," helps explain why ibogaine does not induce catalepsy unlike other VMAT2 inhibitors.